PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer

BACKGROUND: Trastuzumab is an active agent against human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC). This study aimed to characterize resistance to trastuzumab-based front-line chemotherapy in HER2+ GC patients and to establish factors predictive of this resistance. RESUL...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Kim, Chan, Lee, Choong-Kun, Chon, Hong Jae, Kim, Joo Hoon, Park, Hyung Soon, Heo, Su Jin, Kim, Hyun Jeong, Kim, Tae Soo, Kwon, Woo Sun, Chung, Hyun Cheol, Rha, Sun Young
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5768341/
https://ncbi.nlm.nih.gov/pubmed/29371924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23054
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky